Eli Lilly's Weight-Loss Drug Revenue Grows Despite Decline in GLP-1 Insurance Coverage
Employer coverage for GLP-1 weight-loss drugs has dropped from 72% to 60%, raising concerns about the sustainability of Eli Lilly’s (NYSE:LLY) growth. However, LLY reported $22.97 billion in Q2 revenue—a 48% year-over-year increase—driven by strong volume growth for its obesity drug Zepbound and diabetes treatment Mounjaro. Despite a decline in realized prices of about 13%, prescription volumes surged by 60%. Roughly half of new Zepbound prescriptions are now filled as self-pay, indicating patients are increasingly paying out-of-pocket due to reduced insurance coverage. Employers cite high upfront costs and limited short-term savings from GLP-1 drugs as reasons for pulling back. Lilly is adapting with direct-to-consumer pricing models such as its Employer Connect program ($449/month) and the Medicare Bridge Program ($50/month). These options are helping maintain access to Zepbound even where commercial coverage narrows, suggesting that while margin expansion may slow, volume growth remains robust.
Topics: Eli Lilly revenue GLP-1 drugs insurance coverage Mounjaro Zepbound